Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
13 06 2023
Historique:
medline: 15 6 2023
pubmed: 14 6 2023
entrez: 13 6 2023
Statut: epublish

Résumé

To describe long term breast cancer mortality among women with a diagnosis of breast cancer in the past and estimate absolute breast cancer mortality risks for groups of patients with a recent diagnosis. Population based observational cohort study. Routinely collected data from the National Cancer Registration and Analysis Service. All 512 447 women registered with early invasive breast cancer (involving only breast and possibly axillary nodes) in England during January 1993 to December 2015, with follow-up to December 2020. Annual breast cancer mortality rates and cumulative risks by time since diagnosis, calendar period of diagnosis, and nine characteristics of patients and tumours. For women with a diagnosis made within each of the calendar periods 1993-99, 2000-04, 2005-09, and 2010-15, the crude annual breast cancer mortality rate was highest during the five years after diagnosis and then declined. For any given time since diagnosis, crude annual breast cancer mortality rates and risks decreased with increasing calendar period. Crude five year breast cancer mortality risk was 14.4% (95% confidence interval 14.2% to 14.6%) for women with a diagnosis made during 1993-99 and 4.9% (4.8% to 5.0%) for women with a diagnosis made during 2010-15. Adjusted annual breast cancer mortality rates also decreased with increasing calendar period in nearly every patient group, by a factor of about three in oestrogen receptor positive disease and about two in oestrogen receptor negative disease. Considering just the women with a diagnosis made during 2010-15, cumulative five year breast cancer mortality risk varied substantially between women with different characteristics: it was <3% for 62.8% (96 085/153 006) of women but ≥20% for 4.6% (6962/153 006) of women. These five year breast cancer mortality risks for patients with a recent diagnosis may be used to estimate breast cancer mortality risks for patients today. The prognosis for women with early invasive breast cancer has improved substantially since the 1990s. Most can expect to become long term cancer survivors, although for a few the risk remains appreciable.

Identifiants

pubmed: 37311588
doi: 10.1136/bmj-2022-074684
pmc: PMC10261971
doi:

Substances chimiques

Receptors, Estrogen 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e074684

Commentaires et corrections

Type : ErratumIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: support from Cancer Research UK, the National Institute for Health Research Oxford Biomedical Research Centre, the UK Medical Research Council, and the University of Oxford for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

BMC Cancer. 2012 Jul 28;12:317
pubmed: 22838641
N Engl J Med. 2007 Apr 19;356(16):1670-4
pubmed: 17442911
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
JAMA Netw Open. 2020 Jun 1;3(6):e208249
pubmed: 32573707
Lancet. 2012 Feb 4;379(9814):432-44
pubmed: 22152853
N Engl J Med. 2012 Nov 22;367(21):1998-2005
pubmed: 23171096
Breast Cancer Res Treat. 2018 Aug;170(3):647-656
pubmed: 29693227
Eur J Cancer. 2018 Oct;102:82-94
pubmed: 30144661
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Cancer Treat Rev. 2022 Apr;105:102375
pubmed: 35367784
Acta Oncol. 2019 Jan;58(1):45-51
pubmed: 30513223
J Clin Oncol. 2016 Sep 20;34(27):3355-7
pubmed: 27458289
Cancer. 2018 Sep 1;124(17):3500-3509
pubmed: 30189117
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Breast Cancer Res. 2010;12(1):R1
pubmed: 20053270
Lancet. 2011 Jan 8;377(9760):127-38
pubmed: 21183212
J Cancer. 2020 Jul 31;11(19):5782-5791
pubmed: 32913471
Breast. 2022 Feb;61:43-57
pubmed: 34896693
Breast Cancer Res Treat. 2015 Jul;152(1):209-216
pubmed: 26041688
Int J Cancer. 2021 May 1;148(9):2289-2303
pubmed: 33252836

Auteurs

Carolyn Taylor (C)

Nuffield Department of Population Health, University of Oxford, Oxford, UK carolyn.taylor@ndph.ox.ac.uk.
Oxford University Hospitals, Oxford, UK.

Paul McGale (P)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Jake Probert (J)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

John Broggio (J)

National Disease Registration Service (NDRS), NHS England, Birmingham, UK.

Jackie Charman (J)

National Disease Registration Service (NDRS), NHS England, Birmingham, UK.

Sarah C Darby (SC)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Amanda J Kerr (AJ)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Timothy Whelan (T)

Department of Oncology, McMaster University and Juravinski Cancer Centre, Hamilton, ON Canada.

David J Cutter (DJ)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Oxford University Hospitals, Oxford, UK.

Gurdeep Mannu (G)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.

David Dodwell (D)

Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Oxford University Hospitals, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH